References
- Taichman DB, Mandel J. Epidemiology of pulmonary arterial hypertension. Clin Chest Med 2007;28:1-22
- D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-9
- Trulock EP, Edwards LB, Taylor DO, et al. Registry of the international society for heart and lung transplantation: twenty-second official adult lung and heart–lung transplant report – 2005. J Heart Lung Transplant 2005;24:956-67
- Stewart DJ, Levy RD, Cernacek P, et al. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991;114:464-9
- Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-9
- Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004;61:227-37
- Buckley MS, Wicks LM, Staib RL, et al. Pharmacokinetic evaluation of ambrisentan. Expert Opin Drug Metab Toxicol 2011;7:371-80
- Yoshida S, Shirato K, Shimamura R, et al. Efficacy, safety, and pharmacokinetics of ambrisentan in Japanese adults with pulmonary arterial hypertension. Curr Med Res Opin 2011;27:1827-34
- Oudiz RJ, Galie N, Olschewski H, et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:1971-81
- McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005;25:244-9
- Rubin LJ, Badesch DB, Fleming TR, et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest 2011;140:1274-83
- Klinger JR, Oudiz RJ, Spence R, et al. Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension. Am J Cardiol 2011;108:302-7